Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
— Recorded Second Quarter Revenue of $25.4 Million —
— Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million —
Related news for (CDMO)
- Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand
- Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand
- Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction
- Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
- Cannell Capital LLC Intends to Vote Against Proposed Acquisition of Avid Bioservices by GHO Capital and Ampersand Capital